L. Tookman

发表

Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.

A. Shibata, I. McNeish, M. Flak, 2011, The Journal of clinical investigation.

The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic.

S. Dickson, A. K. Hewson, L. Tung, 2002, Diabetes.

Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma

A. Matakidou, T. Powles, J. Shamash, 2013, Acta oncologica.

Polymeric Carriers for Delivery of RNA Cancer Therapeutics

L. Castellano, A. Frampton, J. Krell, 2022, Non-coding RNA.

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

I. McNeish, F. Balkwill, K. Vousden, 2016, Cancer research.

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma

F. Markowetz, Philip Smith, J. Brenton, 2021, bioRxiv.

Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

J. Brenton, I. McNeish, T. Crook, 2015, Molecular oncology.

Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management

N. Rahman, H. Gabra, I. McNeish, 2020, Scientific Reports.

New drugs for breast cancer.

R. Roylance, L. Tookman, Laura Tookman, 2010, British medical bulletin.

Response to the letter entitled “Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers”

I. McNeish, Alireza Samani, L. Tookman, 2022, ESMO open.

Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

S. K. Ghosh, I. McNeish, A. Montes, 2022, ESMO open.

Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting

I. McNeish, J. Krell, L. Tookman, 2020, Therapeutic advances in medical oncology.

Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.

I. McNeish, K. Pirlo, Yaohe Wang, 2015, Cancer research.

RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer

A. Shibata, I. McNeish, C. Ingemarsdotter, 2015, Molecular Cancer Research.

Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.

I. McNeish, K. Pirlo, A. Willis, 2012, Molecular Therapy.

Changing practice to improve pain control for renal patients

L. Fishman, E. Brown, D. Game, 2009, Postgraduate Medical Journal.

Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

Stephen S. Taylor, J. Brenton, J. Ledermann, 2023, International Journal of Gynecological Cancer.

Safe administration of chemotherapy in mast cell activation syndrome

I. McNeish, J. Krell, L. Tookman, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.